NWBO - Northwest Biotherapeutics locks Phase III trial data

Northwest Biotherapeutics ([[NWBO]] +2.6%) announced that the database for the Phase III trial of DCVax-L for Gliobastoma has been locked.Pipeline:Independent service firms managing the clinical trial will now arrange for the independent statisticians to have access to the unblinded raw data from the trial."We are hopeful that DCVax-L can become an important new treatment option for patients who urgently need more and better treatments for Glioblastoma brain cancer," CEO Linda Powers commented.

For further details see:

Northwest Biotherapeutics locks Phase III trial data